Feb 4, 2026 07:09AM H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)

Jan 23, 2026 06:49AM H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)

Jan 22, 2026 07:01AM Invivyd partners with skier Lindsey Vonn for antibody education campaign

Jan 21, 2026 04:16AM BTIG Reiterates Buy Rating on Invivyd Inc. (IVVD)

Jan 8, 2026 07:08AM Invivyd reports $17.2 million Q4 revenue, up 25% year-over-year

Dec 23, 2025 07:05AM Invivyd receives FDA fast track status for COVID antibody VYD2311

Dec 22, 2025 06:00AM BTIG Starts Invivyd Inc. (IVVD) at Buy

Nov 25, 2025 07:06AM D. Boral Capital Downgrades Invivyd Inc. (IVVD) to Hold

Nov 24, 2025 07:01AM Invivyd identifies RSV antibody candidate VBY329 for pediatric prevention

Nov 6, 2025 08:16AM Invivyd, Inc. (IVVD) Tops Q3 EPS by 1c

Nov 3, 2025 06:46AM Invivyd Inc. (IVVD) PT Raised to $10 at H.C. Wainwright

Oct 6, 2025 07:01AM Invivyd receives FDA clearance for COVID antibody drug trials

Oct 6, 2025 06:16AM Cantor Fitzgerald Starts Invivyd Inc. (IVVD) at Overweight, PT $10

Oct 2, 2025 04:15PM Invivyd (IVVD) files $350M mixed shelf

Sep 16, 2025 06:57AM H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)

Aug 19, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)

Aug 18, 2025 04:33PM Invivyd reports antibody maintains activity against XFG covid variant

Aug 15, 2025 06:56AM Invivyd, Inc. (IVVD) Misses Q2 EPS by 10c

Aug 14, 2025 04:47PM Invivyd receives FDA guidance for COVID-19 antibody approval pathway

Jul 23, 2025 07:03AM Invivyd adds Yale scientist to long COVID antibody study group

Jul 21, 2025 07:07AM Invivyd says NCCN updated cancer guidelines for COVID-19 prevention

Jul 2, 2025 07:01AM Invivyd (IVVD) and Leading Researchers Form SPEAR Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jun 27, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)

Jun 26, 2025 07:01AM Invivyd (IVVD) Announces Positive Full Phase 1/2 Clinical Data for VYD2311

May 29, 2025 06:52AM Invivyd Inc. (IVVD) PT Lowered to $5 at H.C. Wainwright

May 23, 2025 07:02AM Invivyd (IVVD) Announces Inclusion of PEMGARDA in NCCN Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 15, 2025 04:36PM Invivyd, Inc. (IVVD) Misses Q1 EPS by 12c

May 14, 2025 07:05AM Invivyd (IVVD) Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 12, 2025 07:01AM Invivyd (IVVD) Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Apr 21, 2025 07:01AM Invivyd (IVVD) Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Mar 26, 2025 04:17PM Invivyd (IVVD) Appoints Ajay Royan to its Board

Mar 5, 2025 07:05AM Invivyd (IVVD) Announces Continued Neutralizing Activity of PEMGARDA Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Feb 24, 2025 07:06AM Invivyd (IVVD) Announces FDA Declined Request to Expand Existing Emergency Use Authorization of PEMGARDA

Feb 4, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)

Feb 3, 2025 07:02AM Invivyd (IVVD) Announces Positive Phase 1/2 Clinical Data for VYD2311

Jan 27, 2025 07:01AM Invivyd (IVVD) Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request

Jan 10, 2025 07:08AM Invivyd (IVVD) Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Nov 14, 2024 04:26PM Invivyd, Inc. (IVVD) Misses Q3 EPS by 18c

Oct 30, 2024 07:15AM EF Hutton Starts Invivyd Inc. (IVVD) at Buy

Oct 1, 2024 07:08AM Invivyd (IVVD) Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

Sep 23, 2024 07:08AM Invivyd (IVVD) Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA

Sep 4, 2024 07:03AM Invivyd (IVVD) Doses First Participants in Phase 1 Clinical Trial of VYD2311

Sep 3, 2024 07:01AM Invivyd (IVVD) Announces Continued Neutralizing Activity of PEMGARDA Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1

Sep 3, 2024 06:48AM H.C. Wainwright Reiterated Invivyd Inc. (IVVD) at Buy

Aug 28, 2024 06:47AM H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)

Aug 27, 2024 07:02AM Invivyd (IVVD) Announces PEMGARDA Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Aug 15, 2024 06:05AM Invivyd, Inc. (IVVD) Misses Q2 EPS by 3c

Jul 1, 2024 07:03AM Invivyd (IVVD) Announces its Addition to the Russell 2000 and Russell 3000 Indexes

Jun 14, 2024 07:02AM Invivyd (IVVD) Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants